A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous FL058 and Meropenem Alone and in Combination in Healthy Chinese Subjects
Latest Information Update: 30 Sep 2021
At a glance
- Drugs FL 058 (Primary) ; Meropenem (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 30 Sep 2021 New trial record